CTK7A
CTK7A is a curcumin derivative with anticancer activity by inhibiting the HAT activity of p300 and reducing the autoacetylation of p300, thereby affecting its interaction with HIF-1α. The inhibition of CTK7A leads to decreased HIF-1α accumulation and activity, which can be used for cancer treatment research[1].
Product Specifications
CAS Number
1297262-16-8
UNSPSC
12352005
Target
Epigenetic Reader Domain; HIF/HIF Prolyl-Hydroxylase; Histone Acetyltransferase
Type
Reference compound
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ctk7a.html
Smiles
COC(C=C1/C=C/C2=CC(/C=C/C3=CC(OC)=C(C=C3)O)=NN2C4=CC=C(C=C4)C(O[Na])=O)=C(C=C1)O
Molecular Formula
C28H23N2NaO6
Molecular Weight
506.48
References & Citations
[1]Rath S, et al. CTK7A, a curcumin derivative, can be a potential candidate for targeting HIF-1α/p300 complex: Evidences from in vitro and computational studies[J]. Biophysical Chemistry, 2022, 287: 106828.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880460-500 1x 500 µL
CD44 Standard (156-3C11), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041683-100 1x 100 µL
Factor XIIIa (Coagulation Factor XIIIA Chain) (F13A1/1683), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042965-100 1x 100 µL
C1QB / Complement C1q B-Chain (C1QB/2965), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details